Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2013

01.09.2013 | short review

Georgia on my mind: multiple myeloma highlights at ASH 2012

verfasst von: Dr. Wolfgang Willenbacher, MD, Dr. Ella Willenbacher, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Clonal evolutionary models of myeloma progression were the main focus with respect to basic science highlights at ASH 2012. The well-documented evidence for the existence of a “Darwinian-branching” evolution pattern has major clinical implications for the development of new treatment strategies and disease monitoring. As treatment results for myeloma have been further improved in most patient cohorts, an easy to use score for identification of high-risk patients with shortened overall survival (OS) has been established (elevated LDH, International Staging System (ISS) stage 3 disease, presence of cytogenetic aberrations t(4;14) and/or del 17p), while further evidence supporting the use of cereblon expression as a biomarker of IMiD (Thalidomid, Lenalidomide, Pomalidomide (POM)) response was presented. Multiple presentations delivered further positive evidence of the usefulness of maintenance and/or consolidation elements in myeloma therapies. A good example came from the Italian VMPT-VT vs. VMP trial proofing both a considerable progression free (11 months)—and OS benefit in a large phase III setting, comparing a quadruplet induction with doublet maintenance with a standard triplet induction therapy. In relapsed and refractory myeloma with both Bortezomib and IMiD pretreatment, POM and low dose Dexamethason were proved to be superior to high dose Dexamethason in a phase III trial that is expected to lead to drug registration of POM in the near future. Five presentations gave evidence for the applicability of Bendamustin based combination therapies in third and later lines of therapies, with good results even in elderly patients.
Literatur
1.
Zurück zum Zitat Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–48.PubMedCrossRef Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–48.PubMedCrossRef
2.
Zurück zum Zitat Morgan GJ, Kaiser MF. How to use new biology to guide therapy in multiple myeloma. Am Soc Heamtol Edu Program. 2012;2012:342–9. Morgan GJ, Kaiser MF. How to use new biology to guide therapy in multiple myeloma. Am Soc Heamtol Edu Program. 2012;2012:342–9.
3.
Zurück zum Zitat Kumar SK, Dispenzieri A, Gertz MA, et al. Continued improvement in survival in multiple myeloma and the impact of novel agents. Blood. 2012;120:#3972.CrossRef Kumar SK, Dispenzieri A, Gertz MA, et al. Continued improvement in survival in multiple myeloma and the impact of novel agents. Blood. 2012;120:#3972.CrossRef
4.
Zurück zum Zitat Moreau PM, Planche L, Attal M, et al. The combination of ISS 3, high LDH and t(4;14) and/or del(17p) identify a simple prognostic Index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous stem cell transplantation, and allow the definition of a subgroup of patients at high-risk of early death from progressive disease. Blood. 2012;120:#598.CrossRef Moreau PM, Planche L, Attal M, et al. The combination of ISS 3, high LDH and t(4;14) and/or del(17p) identify a simple prognostic Index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous stem cell transplantation, and allow the definition of a subgroup of patients at high-risk of early death from progressive disease. Blood. 2012;120:#598.CrossRef
5.
Zurück zum Zitat Klimowicz A, Neri P, Belch A, et al. High cereblon protein expression correlates with improved response and survival in myeloma patients treated with Lenalidomide. Blood. 2012;120:#931. Klimowicz A, Neri P, Belch A, et al. High cereblon protein expression correlates with improved response and survival in myeloma patients treated with Lenalidomide. Blood. 2012;120:#931.
6.
Zurück zum Zitat Schuster SR, Kortuem KM, Zhu YX, et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. Blood. 2012;120:#194. Schuster SR, Kortuem KM, Zhu YX, et al. Cereblon expression predicts response, progression free and overall survival after pomalidomide and dexamethasone therapy in multiple myeloma. Blood. 2012;120:#194.
7.
Zurück zum Zitat Broyl A, Kuiper R, vanDuin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;1221(4):624–7. doi:10.1182/blood-2012–06-438101.CrossRef Broyl A, Kuiper R, vanDuin M, et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2013;1221(4):624–7. doi:10.1182/blood-2012–06-438101.CrossRef
8.
Zurück zum Zitat Palumbo A, Bringhen S, Rossi D, et al. Overall survival benefit for Bortezomib-Melphalan-Prednisone-Thalidomide followed by maintenance with Bortezomib-Thalidomide (VMPT-VT) versus Bortezomib-Melphalan-Prednisone (VMP) in newly diagnosed multiple myeloma patients. Blood. 2012;120:#200.CrossRef Palumbo A, Bringhen S, Rossi D, et al. Overall survival benefit for Bortezomib-Melphalan-Prednisone-Thalidomide followed by maintenance with Bortezomib-Thalidomide (VMPT-VT) versus Bortezomib-Melphalan-Prednisone (VMP) in newly diagnosed multiple myeloma patients. Blood. 2012;120:#200.CrossRef
9.
Zurück zum Zitat Dimopoulos MA, Lacy MQ, Moreau P. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study. Blood. 2012;120:#LBA-06. Dimopoulos MA, Lacy MQ, Moreau P. Pomalidomide in combination with low-dose dexamethasone: demonstrates a significant progression free survival and overall survival advantage, in relapsed/refractory MM: a phase 3, multicenter, randomized, open-label study. Blood. 2012;120:#LBA-06.
Metadaten
Titel
Georgia on my mind: multiple myeloma highlights at ASH 2012
verfasst von
Dr. Wolfgang Willenbacher, MD
Dr. Ella Willenbacher, MD
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0085-9

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe